Management of febrile neutropenia in low risk cancer patients

Thorax

Volumn 55, Issue SUPPL. 1, 2000, Pages

  Oppenheim, Beryl A ^a   Anderson, Heather ^b  

^a WITHINGTON HOSPITAL   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER; CELL COUNT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HEALTH CARE COST; HUMAN; META ANALYSIS; MULTICENTER STUDY; NEUTROPHIL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; HUMANS; NEOPLASMS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS;

EID: 0033911229     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. 1 Oppenheim BA. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 1998;1(Suppl D):7-11.
2. 2 Klastersky J. Empirical antibiotic therapy in neutropenic cancer patients. Eur J Cancer 1993;29A(Suppl 1):S6-10.
3. 3 Bodey GP. Empirical antibiotic therapy for fever in neutropenic patients. Clin Infect Dis 1993;17(Suppl 2):S378-84.
4. 4 Klastersky J, Glauser MP, Schimpff SC, et al. Prospectiye randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 1986;29:263-70.
5. 5 The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987;317:1692-8.
6. 6 Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13:165-76.
7. 7 Leyland MJ, Bayston KF, Cohen J, et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992;30:843-54.
8. 8 Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell Adulto Infection Program. Antimicrob Agents Chemother 1996;40:1108-15.
9. 9 European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951-8.
10. 10 Meunier F, Zinner SH, Gaya H, et al. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother 1991;35:873-8.
11. 11 Hughes WT, Armstrong D, Bodey GP, et al from the Infectious Diseases Society of America. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25:551-73.
12. 12 Hughes WT, Armstrong D, Bodey GP, et al from the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161: 381-96.
13. 13 Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
14. 14 Freifeld AG, Pizzo PA. The outpatient management of febrile neutropenia in cancer patients. Oncology 1996;10:599-612.
15. 15 Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148:2561-8.
16. 16 Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22.
17. 17 Talcott JA, Whalen A, Clark J, et al. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12: 107-14.
18. 18 The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119:584-93.
19. 19 Karthaus M, Egerer G, Kullmann KH, et al. Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. Eur J Clin Microbiol Infect Dis 1998;17:501-4.
20. 20 Smith L, Will AM, Williams RF, et al. Ceftriaxone vs. azlocillin and netilmicin in the treatment of febrile neutropenic children. J Infect 1990;20:201-6.
21. 21 Preis S, Jurgens H, Friedland C, et al. Ceftriaxone alone or in combination with teicoplanin in the management of febrile episodes in neutropenic children and adolescents with cancer on an outpatient base. Klin Pediatr 1993;205:295-9.
22. 22 Fauser AA, Lang E, Kochling G, et al. A randomized clinical trial of ceftriaxone and teicoplanin versus ceftazidime and teicoplanin as antibiotic therapy in febrile neutropenic cancer patients and bone marrow transplant recipients. Infection 1994;22:271-5.
23. 23 Kubin R. Safety and efficacy of ciprofloxacin in paediatric patients: review. Infection 1993;21:413-21.
24. 24 Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use - safety report. Pediatr Infect Dis J 1997;16:127-9.
25. 25 Cometta A, Calandra T, Bille J, et al. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994;330:1240-1.
26. 26 Kern WV, Markus A, Andriof E. Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients. Eur J Clin Microbiol Infect Dis 1994;13:161-5.
27. 27 Kern WV, Andriof E, Oethinger M, et al. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994;38:681-7.
28. 28 Kelsey SM, Weinhardt B, Collins PW, et al. Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients. Eur J Clin Microbiol Infect Dis 1992;11: 509-14.
29. 29 Griggs JJ, Blair EA, Norton JR, et al. Ciprofloxacin plus piperacillin is an equally effective regimen for empiric therapy in febrile neutropenic patients compared with standard therapy. Am J Hematol 1998;58: 293-7.
30. 30 Chan CC, Oppenheim BA, Anderson H, et al. Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrob Agents Chemother 1989;33:87-91.
31. 31 Malik IA, Abbas Z, Karim M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992;339:1092-6.
32. 32 Malik IA, Khan WA, Aziz Z, et al. Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. Clin Infect Dis 1994;19:522-7.
33. 33 Malik IA, Khan WA, Karim M, et al. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995;98:224-31.
34. 34 Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71:3640-6.
35. 35 Hidalgo M, Hornedo J, Lumbreras C, et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 1999;85:213-9.
36. 36 Schaison G, Eden OB, Henze G, et al. Recommendations on the use of colony-stimulating factors in children: conclusion of a European panel. Eur J Pediatr 1998;157:955-66.
37. 37 American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471-508.
38. 38 American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996;14:1957-60.
39. 39 Croockewit AJ, Bronchud MH, Aapro MS, et al. A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC. Eur J Cancer 1997;33:1732-46.
40. 40 Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341:305-11.
41. 41 Kern WV, Cometta A, de Brock R, et al for the International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999;341: 312-8.
42. 42 Finberg RW, Talcott JA. Fever and neutropenia: how to use a new treatment strategy. N Engl J Med 1999;341:362-3.